Atopic Dermatitis

Omar Noor, MD, and Adelaide A. Hebert, MD, discuss monitoring requirements for various classes of treatments in atopic dermatitis, including topical vs systemic.

Peter A. Lio, MD, reviews treatment options for patients with moderate AD.

At the AAAAI 2023 Annual Meeting, Dr. Debajyoti Ghosh explains the importance of understanding the effect of phthalates, specifically di-2-ethylhexyl phthalate (DEHP).

Matthew Zirwas, MD, shares goals of therapy for a patient with AD.

Expert dermatologists address the clinical implications of boxed warnings of topical treatments in AD.

In an interview segment with Nelson, she described elements from her AAAAI presentation, including when to use biologics or JAK inhibitors and what goes into patch testing for allergic skin reactions.

In his HCPLive interview at the 2023 AAAAI conference, Gallo elaborated on his team’s research into the skin microbiome’s connection to atopic dermatitis and future research.

In an interview with HCPLive, Gallo described his AAAAI presentation on the function of the skin microbiome, as well as the microbiome’s connection to atopic dermatitis.

New data from the 2023 AAAAI conference showed that the mice with atopic dermatitis used in the study had different responses to ILC2 activity depending on their age.

Matthew Zirwas, MD, and Omar Noor, MD, comment on their own experience of time to response with topical and systemic treatments of AD.

Peter A. Lio, MD, discusses the durability of topical treatments in AD, including steroids, calcineurin inhibitors, and JAK inhibitors.

New research into global trends in atopic dermatitis over 3 decades assessed regional and income differences in adolescent eczema patients.

Experts discuss long-term efficacy data for topical medications for the treatment of AD.

Matthew Zirwas, MD, and Omar Noor, MD, review a patient scenario where AD disease activity is limited but in difficult to treat locations.

In another interview segment, Karan Lal, DO, MS, spoke on the side effects of JAK inhibitors and on the FDA approval of abrocitinib for younger atopic dermatitis patients.

During his latest HCPLive interview, Karan Lal, DO, describes some of the major takeaways from his presentations at the South Beach Symposium, including information on atopic dermatitis.

The treatment, developed by Pfizer, has been approved by the FDA for adult patients with atopic dermatitis.

Peter A. Lio, MD, shares his approach to presenting treatment alternatives to patients who want to stop using long-term steroids for treatment of AD.

Adelaide A. Hebert, MD, comments on the need for nondermatologist education on the basics of skin disease care.

A recent study highlighted new information on racial disparities in health care for Black and Hispanic pediatric patients with atopic dermatitis.

New research into egg, peanut allergies and sensitization raised questions about allergy incidence rates and early exposure.

In a recent analysis of 6 trials examining the use of dupilumab, the drug was found to be useful alongside concomitant TCS for patients with erythrodermic atopic dermatitis.

Expert dermatologists discuss the durability of long-term use of topical steroids for treatment of atopic dermatitis.

Adelaide A. Hebert, MD, reviews the use of long-term steroids for treatment of atopic dermatitis.

New research into risk factors for pediatric liver transplant patients indicated that atopy and allergy may follow a transplant and are more common among females and younger patients.

New research into atopic dermatitis treatment indicated that topical JAK inhibitors were safe and effective, although more research is needed regarding adverse effects.

In new research, an association between food allergies and atopic dermatitis was highlighted, suggesting the need for further research.

Experts in dermatology discuss which disease characteristics play the biggest role in influencing treatment choice or change of treatment from the perspective of a patient with atopic dermatitis.

A panel of expert dermatologists comments on newly approved and traditional treatment options, addressing how they target inflammation and the pathophysiology of atopic dermatitis (AD).

New research connected dupilumab levels to OSD in atopic dermatitis patients, indicating a contribution to the development of the condition.